Mkt Cap$2.15T+0.83%
24h Vol$103.14B
BTC Dom55.8%
ETH Dom8.8%
F&G13Extreme Fear
BTC$59,815.00+0.91% ETH$1,558.83-0.24% USDT$0.9985+0.02% BNB$560.94+1.77% USDC$0.99970.00% XRP$1.04+1.36% SOL$70.37+8.55% TRX$0.3195-1.11% FIGR_HELOC$1.03+0.59% HYPE$63.84+6.54% DOGE$0.0743+1.66% RAIN$0.0157-0.39% USDS$0.99950.00% LEO$9.28-0.56% ZEC$406.04+2.85% XLM$0.1747-0.99% BTC$59,815.00+0.91% ETH$1,558.83-0.24% USDT$0.9985+0.02% BNB$560.94+1.77% USDC$0.99970.00% XRP$1.04+1.36% SOL$70.37+8.55% TRX$0.3195-1.11% FIGR_HELOC$1.03+0.59% HYPE$63.84+6.54% DOGE$0.0743+1.66% RAIN$0.0157-0.39% USDS$0.99950.00% LEO$9.28-0.56% ZEC$406.04+2.85% XLM$0.1747-0.99%

Boston Scientific Corporation (BSX) Reports $0.50 Adjusted EPS, $3.73B Revenue for Q3

Boston Scientific reports Q3 results with a strong revenue of $3.73 billion and an adjusted EPS of $0.50.

"BSX's Q3 Earnings: Achieves $0.50 Adjusted EPS, Exceeding $3.73 Billion Revenue Prediction
Image courtesy of 123rf.com
Editorial disclosureRead more

All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

Boston Scientific Corporation (BSX) has demonstrated a robust performance in the third quarter of 2023, underpinned by significant growth across its various segments. The company reported net sales of $3.527 billion, marking an 11.2% increase compared to the same period last year. This growth is even more pronounced on an operational and organic basis, with figures of 11.1% and 10.2%, respectively.

BSX Reports $0.50 EPS and $3.73B in Revenue for Fiscal Q3

Earnings per share (EPS) also showed a positive trend, with a reported EPS of $0.34, significantly higher than the $0.12 in Q3 2022. Adjusted EPS was $0.50, compared to $0.43 in the prior year, reflecting the company’s effective management and strategic initiatives.

Boston Scientific’s performance this quarter has exceeded the market expectations set for them. Analysts had anticipated an EPS of $0.51 and revenue of $3.6 billion. However, the company reported an adjusted EPS of $0.50 and revenue of $3.73 billion. While slightly below the expected EPS, the company’s revenue aligns closely with forecasts.

Guidance

Boston Scientific has issued optimistic guidance for the fourth quarter of 2023, setting high expectations for continued growth. The company forecasts reported net sales growth between 9% and 11% and an adjusted EPS range of $0.49 to $0.52.

These projections indicate confidence in sustained momentum and operational efficiency. For the full year of 2023, the guidance includes an expected reported net sales growth of around 11% and an adjusted EPS of $1.99 to $2.02. This forward-looking outlook underscores the company’s strategic initiatives and its commitment to delivering value to its stakeholders.

Disclaimer: The author does not hold or have a position in any securities discussed in the article.


Tim Fries

Tim Fries

Author · Tokenist

Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.

Related Stories